Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients.

Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients. J Crohns Colitis. 2019 Aug 29;: Authors: Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M Abstract BACKGROUND AND OBJECTIVES: Vedolizumab has demonstrated efficacy and safety in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Endoscopic outcome data are limited, especially in anti-TNF naïve patients. The present study compared endoscopic outcome in anti-TNF naïve and exposed patients, and explored…

Read More

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-Marketing Data.

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-Marketing Data. J Crohns Colitis. 2019 Aug 13;: Authors: Cohen RD, Bhayat F, Blake A, Travis S Abstract BACKGROUND AND AIMS: Vedolizumab is a gut-selective antibody to α4β7 integrin approved to treat moderate-to-severe ulcerative colitis and Crohn’s disease in adults. Clinical trial data on patients meeting protocol-specified criteria may not reflect real-world clinical practice. This is a descriptive analysis of 4 years of post-marketing safety data on vedolizumab. METHODS: The Vedolizumab Global Safety Database contains…

Read More

Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.

Related Articles Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 Sep 04;: Authors: Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ Abstract BACKGROUND: There has been limited evaluation of the association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases (IBD). AIM: To perform a systematic review and meta-analysis to evaluate the potential role of therapeutic drug monitoring (TDM) for vedolizumab. METHODS: Through a systematic…

Read More

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2019 Aug 27;: Authors: Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D’Haens G, Vermeire S Abstract BACKGROUND & AIMS: Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of vedolizumab for maintenance treatment. Vedolizumab SC was investigated as maintenance treatment in patients with moderately to severely…

Read More

Expression Levels of 4 Genes in Colon Tissue Might be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases.

Related Articles Expression Levels of 4 Genes in Colon Tissue Might be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Aug 22;: Authors: Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, Ferrante M Abstract BACKGROUND & AIMS: We aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab therapy. METHODS: We obtained biopsies from inflamed colon…

Read More

Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics.

Related Articles Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics. J Crohns Colitis. 2019 Jul 20;: Authors: Novello M, Stocchi L, Steele SR, Holubar SD, Duraes LC, Kessler H, Shawki S, Hull LT Abstract BACKGROUND AND AIM: The effects of vedolizumab (VEDO) exposure on perioperative outcomes following surgery for inflammatory bowel disease (IBD) remain controversial. The aim of our study was to compare postoperative morbidity of IBD surgery following treatment with VEDO vs. other biologics or no biologics. METHODS: An…

Read More

Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease.

Related Articles Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019 Jul 04;: Authors: Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein J, Feagan BG Abstract BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn’s disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy. METHODS: We performed a phase 3b, open-label, single-group study of…

Read More

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease.

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease. Gastroenterology. 2019 Jun 05;: Authors: Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, Janneke van der Woude C, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D’Haens G Abstract BACKGROUND & AIMS: We evaluated the ability of vedolizumab to induce endoscopic and histologic remission in patients with Crohn’s disease (CD). METHODS: We performed a prospective study of 110 patients with active CD, based on CD activity…

Read More
<< Go Back